Insider Transaction Report for AMICUS THERAPEUTICS, INC.

On April 27, 2026, Samantha Prout, Chief Accounting Officer of AMICUS THERAPEUTICS, INC. (FOLD), reported the disposition of 125,951 shares of Common Stock at a price of $14.50 per share. This transaction occurred in connection with the acquisition of the issuer by BioMarin Pharmaceutical Inc. Additionally, Prout reported the disposition of stock options (right to buy) for a total of 262,447 shares of Common Stock. These options were cancelled and converted into the right to receive a cash payment based on the difference between $14.50 per share and the exercise price. All reported options were fully vested at the time of the transaction. Following these transactions, the post-transaction shares owned are reported as zero.